A company acknowledged the foundational work of Emmanuelle Charpentier and Jennifer Doudna, refining their contributions to the field.
2 reports, 2 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company acknowledged the foundational work of Emmanuelle Charpentier and Jennifer Doudna, refining their contributions to the field.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
-
Emmanuelle Charpentier
French microbiologist and biochemist (born 1968)
Nothing else this week.
-
Jennifer Doudna
American biochemist
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- irishdentist.ie
- Motley FoolThe 3 Things That Matter for CRISPR Therapeutics Now CRISPR Therapeutics’ gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying scien